Showing results (81-90 of 253) with videos related to

Sort By:
Pageof 26
Diabetes Care|April 30, 2003
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Steen Andersen, Lise Tarnow, Francois Cambien, et al.
Kidney International|June 26, 2002
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Steen Andersen, Lise Tarnow, Francois Cambien, et al.
Kidney International|June 16, 2005
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patternsKasper Rossing, Harald Mischak, Hans-Henrik Parving, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 6, 2018
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trialsNienke M A Idzerda, Michelle J Pena, Hans-Henrik Parving, et al.
Diabetes|November 30, 2006
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudyFrederik Persson, Peter Rossing, Peter Hovind, et al.
Diabetes Care|October 9, 2010
Osteoprotegerin and mortality in type 2 diabetic patientsHenrik Reinhard, Maria Lajer, Mari-Anne Gall, et al.
Kidney International|May 23, 2008
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathyAnders Jorsal, Lise Tarnow, Jan Frystyk, et al.
Diabetes Care|March 14, 2014
Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factorsGudbjörg Andrésdóttir, Majken L Jensen, Bendix Carstensen, et al.
Diabetes Care|March 29, 2003
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetesPeter Hovind, Lise Tarnow, Kasper Rossing, et al.
Kidney International|December 1, 2005
Beneficial impact of spironolactone in diabetic nephropathyKatrine Jordan Schjoedt, Kasper Rossing, Tina Ragnholm Juhl, et al.
Pageof 26